Everfront Biotech will be participating in BIO ASIA-Taiwan 2023, the largest biotechnology event in Asia, from July 27th to July 30th, 2023. This is an unmissable international biotech extravaganza, and we welcome your visit to our booth.
【 BIO Asia-Taiwan Exhibition, part of the BIO Asia-Taiwan conference series 】
- Exhibition Dates
Date: 2023/7/27(Thu) – 7/30(Sun)
Time: 10:00 AM ~ 6:00 PM (Last day closes at 5:00 PM)
- Exhibition Place
Taipei Nangang Exhibition Center, Hall 1, 4F
Add: 4F., No.1, Jingmao 2nd Rd., Nangang District, Taipei City 11568, Taiwan Map
- Visiting Eligibility Application
STEP 1. Login / New Member Registration
STEP 2. Please confirm personal basic information to complete the registration procedure
STEP 3. Scan your [Admission QRCode] at the exhibition entrance.
More information: https://expo.bioasiataiwan.com/en/visitor.asp
Everfront Biotech’s booth for this exhibition is located at N814 on the 4th floor of the NSTC INNO ZONE. We look forward to your visit.
Everfront Biotech Holding Company Limited - Brain Cancer Clinical Programs and Research Pipelines
Product Highlights of Cerebraca® Wafer:
Everfront Biotech’s innovative new drug, Cerebraca® Wafer, is a precision medicine sustained-release wafer that revolutionizes the treatment of malignant brain cancer. Through multiple patented novel features, Cerebraca® Wafer has successfully addressed the challenges of treating malignant brain cancer, which is difficult to manage and prone to relapse. Chemotherapy gradually loses its effectiveness against brain cancer cells due to their drug resistance, and the high proportion of cancer stem cells further exacerbates the problem of cancer recurrence and treatment resistance. However, these issues can be addressed by the pharmacological mechanism of action of Cerebraca® Wafer. In addition, malignant brain cancer cells express PD-L1, which renders the immune system unable to kill cancer cells. The successful development of Cerebraca® Wafer has also addressed this issue. In Phase I clinical trials, Cerebraca® Wafer has demonstrated efficacy without any drug-related adverse reactions. The median or average cumulative survival of relapsed malignant brain cancer patients has reached 25-26 months, which is significantly better than existing strategies such as Gliadel® wafer implantation (6.4 months), Temodal capsules (5.8 months), or Avastin injection (9.4 months). Cerebraca® Wafer has been approved by the Taiwan Ministry of Health and Welfare and the Human Research Ethics Committee of Hualien Tzu Chi Hospital for compassionate use trials. For malignant brain cancer patients who cannot undergo surgery and have tumors growing at the cervical spine, implanting Cerebraca® Wafer through a small incision has resulted in tumor shrinkage. In addition, combining Cerebraca® Wafer with cytokine-induced killer cells (CIK) for treatment can achieve a recurrence-free survival period of more than 40 months. With its outstanding clinical results, Everfront Biotech Inc. is actively seeking partners to jointly develop this new drug and help more malignant brain cancer patients.
Introduction to Everfront Biotech Co., Ltd:
Everfront Biotech Inc. was founded in 2010, with a focus on research and development of new drugs, specifically the screening and further development of potential small molecules for clinical study. The company’s team is responsible for all aspects of product development, from front-end potential product development to pre-clinical research, chemistry manufacturing and controls (CMC), clinical trial submissions, and clinical trial planning and execution. To date, the Everfront Biotech team has successfully applied three clinical trials: Cerebraca® Wafer (for malignant brain tumors), HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer), which have been approved for IND applications in both the United States and Taiwan.
Everfront Biotech’s new drug development is in line with national policies, and the Cerebraca® Wafer and HK-001 products were granted the certifications of biotech and new drug in 2016. The company has received the government subsidies in three science and technology projects as of 2022 from the Ministry of Economic Affairs.